Valneva, chikungunya

MHRA approves Valneva’s chikungunya vaccine Ixchiq for use in adults
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent disease caused by the chikungunya virus (CHIKV) in individuals aged 18 years and older.
Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults. France-based Valneva has also submitted label extension applications in the US,
MHRA grants Valneva marketing authorization for chikungunya vaccine
Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United
Valneva rises after U.K. approval of chikungunya vaccine
Shares of Valneva (NASDAQ:VALN) traded higher on Wednesday after the French biotech announced that the U.K.’s Medicines and Healthcare Products Regulatory Agency granted marketing authorization for its chikungunya vaccine.
Chikungunya ‘stooping disease’ explained as UK approves first vaccine
The world’s first vaccine for mosquito-borne chikungunya virus has been approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The disease strikes around half a million people every year and climate change has increased the risk of transmission in Europe. So what is it and why do we need a vaccine?
Valneva jumps 19% after chikungunya vaccine wins UK approval
Shares of Valneva (VALN), a specialty vaccine company closed up over $1.00 per share or almost 19% to close the regular session at $6.67 per
Valneva receives authorisation for world’s first Chikungunya vaccine
Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is indicated for active immunisation for the prevention of disease caused by Chikungunya virus (CHIKV) in individuals 18 years of age and older.
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci
UK grants approval for Valneva’s chikungunya vaccine
French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), marking the fourth regulatory approval for the world’s first vaccine against the virus.
pharmaphorum4d
CHMP backs Bavarian Nordic's chikungunya jab
Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...
Medscape6d
EMA Expedites Adolescent Chikungunya Vaccine Recommendation
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...
Morningstar6d
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets ...
FiercePharma3d
Valneva snares $33M contract to supply US with Japanese encephalitis vaccine
While much of Valneva's focus these days is centered on its landmark vaccine for chikungunya virus, the French immunization ...